(NASDAQ: LUNG) Pulmonx's forecast annual revenue growth rate of 19.59% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 9.07%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.5%.
Pulmonx's revenue in 2026 is $90,497,000.On average, 8 Wall Street analysts forecast LUNG's revenue for 2026 to be $4,059,459,818, with the lowest LUNG revenue forecast at $3,750,156,780, and the highest LUNG revenue forecast at $4,370,283,394. On average, 7 Wall Street analysts forecast LUNG's revenue for 2027 to be $4,936,684,287, with the lowest LUNG revenue forecast at $4,139,245,894, and the highest LUNG revenue forecast at $6,704,311,232.
In 2028, LUNG is forecast to generate $6,745,281,319 in revenue, with the lowest revenue forecast at $4,917,255,173 and the highest revenue forecast at $9,951,507,399.